First Trust Nasdaq Pharmaceuticals ETF (FTXH) Research
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Market snapshot
- Symbol
- FTXH
- Price
- $35.38
- Day change
- -0.74%
- Market cap
- $33.6M
- 52-week range
- 25.37-36.277
- Sector
- Financial Services
- Industry
- Asset Management - Global
Recent news
- Trump to announce discount drug pricing expansion, White House official says
U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday, a White House official said.
- Could pressure to make money faster kill the next lifesaving pill?
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Peer companies
- First Trust Nasdaq Food & Beverage ETF (FTXG)
- Hedgeye Capital Allocation ETF (HECA)
- JPMorgan Active China ETF (JCHI)
- Leuthold Select Industries ETF (LST)
- Overlay Shares Small Cap Equity ETF (OVS)
- Putnam Emerging Markets Ex-China ETF (PEMX)
- Rayliant SMDAM Japan Equity ETF (RAYJ)
- Emerging Markets Equity Select ETF (RNEM)
Open First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.